{
    "url_original": "https://www.wsj.com/articles/pfizer-lifts-outlook-on-covid-19-vaccine-posts-weaker-profit-11612270628?mod=business_lead_pos2",
    "url": "pfizer-lifts-outlook-on-covid-19-vaccine-posts-weaker-profit-11612270628",
    "title": "Pfizer Lifts Outlook on Covid-19 Vaccine, Posts Weaker-Than-Expected Profit",
    "sub_head": "Pharmaceutical company expects about $15 billion in 2021 vaccine sales",
    "category_1": "Business",
    "category_2": "Earnings",
    "image_1_url": "https://images.wsj.net/im-293513?width=620&size=1.5",
    "image_1": "im-293513.jpg",
    "time": "2021-02-02 07:57:00",
    "body": "Pfizer Inc.  said it expects to generate about $15 billion in sales for its Covid-19 vaccine this year as it posted higher quarterly revenue, but missed on profit expectations to finish 2020.<br />The New York City-based pharmaceutical company logged 12% revenue growth boosted by its Covid-19 vaccine and strong oncology results.<br />Revenue was $11.68 billion, compared with $10.45 billion in the same quarter a year earlier. Analysts surveyed by FactSet were expecting revenue of $11.48 billion.<br />Pfizer said Tuesday the Covid-19 vaccine it developed with  BioNTech SE  contributed $154 million in revenue in the fourth quarter, helping lift the company’s overall revenue from all vaccines to $2 billion, a 17% year-over-year increase.<br />Oncology revenue grew 23% year over year to $3.02 billion. Sales growth for drugs such as Vyndaqel, a heart medication, Ibrance, for breast cancer, and other oncology drugs helped drive growth in Pfizer’s revenue from therapeutics."
}